This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Change Healthcare (CHNG) Q1 Earnings Miss, Revenues Beat
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal first-quarter results benefit from solid performance across Software and Analytics, Network Solutions and Technology-Enabled segments.
McKesson (MCK) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2022 results benefit from strong performance across all segments.
DaVita (DVA) Beats on Q2 Earnings, Raises 2021 EPS View
by Zacks Equity Research
DaVita's (DVA) strength in dialysis patient service revenues drives its Q2 top line.
PacBio's (PACB) Q2 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
PacBio (PACB) sees strength in Q2 product revenues, led by robust consumable sales.
CVS Health (CVS) Q2 Earnings Beat Estimates, EPS View Up
by Zacks Equity Research
CVS Health (CVS) Q2 adjusted EPS drops year over year on escalating costs and expenses which are putting pressure on margins.
Avanos Medical (AVNS) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Avanos Medical's (AVNS) second-quarter 2021 results gains from strength in Pain Management segment.
Charles River (CRL) Q2 Earnings Beat Estimates, 2021 View Up
by Zacks Equity Research
Robust performance by all three segments drove Charles River's (CRL) revenues in the second quarter.
AmerisourceBergen (ABC) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter results benefit from segmental growth.
Myriad Genetics (MYGN) Q2 Earnings Beat, Gross Margin Rises
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q2 sales despite a challenging business environment.
Earnings Estimates Rising for West Pharmaceutical (WST): Will It Gain?
by Zacks Equity Research
West Pharmaceutical (WST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Zimmer Biomet (ZBH) sales improve across all its operating segments and geographies on recovery from the pandemic in the months of the second quarter.
Henry Schein (HSIC) Q2 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the second quarter.
Bruker (BRKR) Q2 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Bruker (BRKR) reports better-than-expected revenues for the second quarter of 2021 on strong segmental performance driving the top line.
Hill-Rom (HRC) Q3 Earnings Top Estimates, 2021 Guidance Up
by Zacks Equity Research
Hill-Rom (HRC) reports better-than-expected revenues for third-quarter fiscal 2021 with strong segmental performance driving the top line.
Fresenius Medical (FMS) Q2 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across the regions, EMEA, Asia Pacific and Latin America.
OPKO Health's (OPK) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results benefit from strength in both its reportable segments.
Merit Medical's (MMSI) Q2 Earnings Top Estimates, '21 View Up
by Zacks Equity Research
Merit Medical (MMSI), in the second quarter, benefits from revenue growth across both its segments as well as across all the product categories within its Cardiovascular unit.
Integer Holdings (ITGR) Beats on Q2 Earnings, Ups 2021 View
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust segmental performances along with strength in majority of the product lines.
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Faster-than-expected vaccination uptake leads to a reduction in demand for COVID-19 testing for QIAGEN (QGEN) in Q2.
Teleflex (TFX) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Teleflex (TFX) reports better-than-expected revenues with strong segmental and geographical performance driving the top line in second-quarter 2021.
Omnicell (OMCL) Q2 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Omnicell (OMCL) reports better-than-expected revenues on strong segmental performance driving the top line in second-quarter 2021.
Bio-Rad (BIO) Q2 Earnings Top Estimates, 2021 View Raised
by Zacks Equity Research
Strength in Life Science and Clinical Diagnostics segments during the second quarter drove Bio-Rad (BIO) revenues.
IDEXX (IDXX) Q2 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Strength in CAG Diagnostics and Water businesses drove IDEXX's (IDXX) second-quarter revenues.
Edwards Lifesciences (EW) Beats on Q2 Earnings, Margins Up
by Zacks Equity Research
Strong sales growth across all four products along with steady improvement in surgical procedure volumes during the second quarter drove Edwards Lifesciences' (EW) revenues.
DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) second-quarter results benefit from domestic and international revenue growth and solid new customer additions.